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Background: Individuals with diabetes who are smokers have higher risks of cardiovascular disease, premature
death, and microvascular complications. The present study aims to determine the prevalence of symptoms of
depression and anxiety in smokers with type 2 diabetes mellitus (T2D) and to evaluate if the prevalence of
symptoms of depression and anxiety differ between the three groups studied (patients with T2D who smoke;
patients with T2D who do not smoke; smokers without T2D), and finally determine if the degree of nicotine
dependence is related to symptoms of anxiety and depression in smokers (with or without T2D).
Methods: Three study groups were formed: 46 T2D smokers (DS), 46 T2D non-smokers (D), and 46 smokers without
diabetes (S), totaling 138 participants. Hospital Anxiety and Depression (HAD) scale and Fagerström Test were
applied.
Results: The prevalence of symptoms of depression and anxiety in smokers with T2D was 30.4% and 50%,
respectively. There was no significant difference in the proportion of individuals with symptoms of anxiety
(p = 0.072) or depression (p = 0.657) in the DS group compared to group D or S. Among male patients with T2D,
the smokers had a higher prevalence of anxiety symptoms (19.6%) than non-smokers (4,3%) (p = 0,025). The
prevalence of high nicotine dependence among smokers with and without T2D was 39.1% and 37.1%, respectively
(p = 0.999). Fagerström scores showed no significant correlation with the scores obtained on the subscale of anxiety
(p = 0,735) or depression (p = 0,364).
Conclusions: The prevalence of depression and anxiety among smokers with and without diabetes and
non-smokers T2D is similar. Among male individuals with T2D, the smokers have more symptoms of anxiety than
the non-smokers. There is no difference in the prevalence of nicotine dependence among smokers with and
without diabetes. The presence of symptoms of anxiety or depression is similar between patients who are
dependent and not dependent on nicotine.
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Growing evidence suggests an association between smok-
ing and the development of type 2 diabetes (T2D) in
adults [1,2]. A meta-analysis showed that smoking is asso-
ciated with increased risk of developing T2D and that this
phenomenon is dose-dependent [3]. According to Wen
et al., the addition of smoking habit makes the appearance
of diabetes earlier by an average of 4.1 years [2].
According to the International Diabetes Federation,
the estimated prevalence of diabetes in a population
aged between 20 and 79 years is 8.3%, and 80% of those
individuals live in low- and middle-income countries.
Worldwide, approximately 366 million adults are dia-
betics, including 12.4 million in Brazil. T2D accounts
for at least 90% of all cases of diabetes [4]. According
to the World Health Organization, cigarette smoking is
the leading preventable cause of premature death, and
the tobacco epidemic kills nearly six million people per
year [5]. A study in Brazil showed that the prevalence
of smoking in Brazilian capitals varies from 12.9% in
Aracajú to 25.2% in Porto Alegre [6]. Another national
survey found that 17.4% of the sample uses tobacco
daily and that 20.8% of smokers aged ≥ 35 years
reported a desire to stop or reduce tobacco use [7].
This study found that daily consumption of tobacco in
major Brazilian cities is significantly lower so far in the
2000s than at the end of the last century. In contrast, a
study conducted in the U.S. found that the prevalence
of smoking among adults with diabetes (type 1 or 2) in
1990 was 23.6% and remained stable through 2001
(23.2%) [8].
Smokers have increased risks of cardiovascular disease,
premature death, and microvascular complications of dia-
betes [9]. Cigarette smoking increases the risks of nephro-
pathy, retinopathy, diabetic neuropathy [which is more
strongly associated with type 1 diabetes (T1D)], and macro-
vascular complications (more pronounced in T2D) [10].
The intimate relationship of smoking with some psy-
chiatric disorders, especially depression and anxiety, has
been demonstrated [11]. Collins et al. [12] even consider
smoking to be a risk factor for higher scores of anxiety
and depression. Breslau et al. [13] demonstrated in young
adults positive associations between nicotine dependence
and major depression, obsessive compulsive type disor-
ders, phobias, and anxiety disorders, as well as alcohol
and illicit drug use.
Few studies have evaluated smoking in subjects with
diabetes. The study of Spangler et al. [14] is the only
study whose primary objective was to study the psycho-
logical variables in smokers with diabetes. Those authors
found higher levels of stress, depression, and negative
affect (anxiety, guilt, hostility) in smokers than non-
smoking T1D patients. No study aiming to assess
depression and anxiety in T2D smokers was found inthe literature. However, Lloyd et al. [15] found no signif-
icant difference in the prevalence of depression (HAD
scale) among smokers and non-smokers when assessing
symptoms of depression and anxiety in outpatients with
T1D or T2D.
Most smokers, despite the intention to quit, are
unsuccessful. The Fagerström Tolerance Questionnaire
and its revised version Fagerström Test for Nicotine
Dependence (FTND) were specifically developed to eval-
uate the physical dependence to nicotine [16]. Emotional
problems such as depression and anxiety are common in
T2D patients and may impair self-care and glycemic
control [17]. The American Diabetes Association (ADA)
emphasizes that the presence of psychiatric comorbid-
ities such as depression are associated with a higher pre-
valence of smoking and increased risk of relapse after
stopping smoking [18]. The Hospital Anxiety and
Depression (HAD) scale is used to evaluate symptoms of
anxiety and depression [19] and is considered a reliable
indicator of depression in individuals with diabetes [20].
The ADA recommends that all smokers be warned
about the additional risks that smoking causes and be
advised to cease the habit, including alternative forms of
treatment and, in special situations, an evaluation of the
degree of nicotine dependence [9,18].
The symptoms of depression and anxiety are both
associated with smoking [12,14,21] and diabetes [21-26].
So, subjects with diabetes and smokers have two risk
factors, and thus it is possible that they are more likely
to have symptoms of anxiety and depression. The pre-
sence of psychiatric disorders was associated with nico-
tine dependence [11,13]. Thus, it is also expected that
smokers with T2D have a higher degree of nicotine
dependence.
The present study aimed to determine the prevalence of
symptoms of depression and anxiety and the degree of
nicotine dependence in smokers diagnosed with T2D who
were treated at the Endocrinology Clinic in the Clinics
Hospital, Federal University of Uberlândia (HC-UFU).
These prevalences were compared with those found
among the T2D non-smokers and those of the smokers
without diabetes in an attempt to clearly define the role of
each variable in symptomatology. Thus, the degree of
nicotine dependence was also compared between T2D
smokers and non-diabetics smokers. Finally, this study
also aimed determine if the degree of nicotine dependence
is related to symptoms of anxiety and depression in smo-
kers (with or without T2D).
Methods
Between March and November 2009, T2D patients aged
30 and older were interviewed. They were contacted at
the Endocrinology Clinic, HC-UFU. All T2D out-patients
who went to the Endocrinology Clinic were asked if they
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in the study. If the answer was yes, they immediately
filled out the informed consent. The pharmacist
researcher of this study was responsible for interviewing
the patients. All patients gave their written informed
consent for participation.
The diagnosis of T2D was confirmed in the medical
records based on ADA criteria.
Each T2D smoker (case) was paired with one non-
smoking T2D patient (control 1) who was treated in the
same Endocrinology Clinic. The non-diabetic smokers
(control 2) were arranged, by convenience, in the
ophthalmology, angiology and dermatology clinic of the
same hospital.
Sex and age could be potential confounders since
both have association with the prevalence of symptoms
of depression and anxiety [11,21,25,27] and with nico-
tine dependence [28], then the controls were matched
by sex and age, differing ± 3 years.
Patients with no history of diabetes, who were not tak-
ing oral hypoglycemic agents or insulin, and who had
fasting glucose < 126 mg/dL in the last 6 months were
considered non-diabetic. Those who met the above cri-
teria, except for not having undergone this test in the
last 6 months, were subjected to glucometry measured
by capillary at the time of the interview. They were con-
sidered non-diabetic if blood glucose was < 140 mg/dL.
Both T2D and non-diabetic patients were considered
to be smokers when they reported consumed at least one
cigarette per day for the past 6 months. Individuals who
had consumed≤ 100 cigarettes throughout their lives
were considered to be non-smokers. Former smokers
who reported having quit smoking for at least 1 year
were also considered to be non-smokers.
Three groups of patients were formed: patients diag-
nosed with T2D who were smokers (group DS), non-
smoking T2D patients (group D), and non-diabetic smo-
kers (group S).
Exclusion criteria were severe psychiatric disorders; sys-
temic disease, such as cancer, acquired immunodeficiency
syndrome, or leprosy, in the medical record; thyroid-
stimulating hormone< 0.3 mIU/mL or > 10 mIU/mL; use
of antidepressants or antipsychotics; and cognitive deficits
or recent and significant personal problems that, based on
the investigators’ evaluation, could interfere with their
responses.
All patients were interviewed in person by the authors,
who filled out a pre-prepared questionnaire with infor-
mation about education, marital status, alcohol con-
sumption, physical activity, family history and habits
related to smoking, use of antihypertensives and anxioly-
tics, time of diagnosis of T2D, family history of disease,
and the treatments currently used, such as diet and the
use of oral hypoglycemic agents and/or insulin. Theweight and height of patients were measured with
mechanical anthropometric scales, and the body mass
index (BMI) (kg/m2) was based on these measures. Coha-
bitation with a spouse or partner was considered a stable
marital status.
The HAD scale, which has been validated in Brazil by
Botega et al. [19], was used as tool to assess symptoms
of anxiety and depression. This scale was chosen because
insomnia, fatigue, and weight loss, which could also be
symptoms of physical illness, do not appear on this scale,
which is focused on symptoms of anhedonia [19]. The
HAD scale was applied by two psychology students who
were previously trained by a psychologist specialized in
health psychology. A score ≥ 8 points on the subscale
HAD-A or HAD-D was considered indicative of clinically
significant symptoms of anxiety or depression, respectively.
The FTND, adapted to the Brazilian population of
smokers, was used as a tool to assess the degree of nico-
tine dependence. A score ≥ 6 indicates high dependence,
and a score ≤ 5 indicates medium or low nicotine depen-
dency [29].
Comparisons between groups were performed using
Student's t-test for variables with normal distribution
(Lilliefors test) and the Mann–Whitney U-test for vari-
ables with non-normal distribution. Analysis of variance
(normal distribution of waste) and the Kruskal-Wallis
test (Dunn) as a non-parametric test were used to com-
pare three groups. The χ2 test was used to evaluate the
relationships between qualitative variables. To verify the
existence of a correlation between the scores or other
values, Pearson's correlation was used. By logistic
regression, we obtained the odds ratios (ORs) of anxi-
ety, depression, nicotine dependence, and other factors.
For variables that showed statistical significance, we
performed multiple logistic regression. We used the
significance level of 5%. BioEstat 5.0 software was used
for statistical analysis [30].
The present study was approved by the ethics commit-
tee of Federal University of Uberlândia (protocol: 042/09).
Results
We recruited 187 patients, five of whom were unwilling
to participate and 44 who met the exclusion criteria. We
therefore evaluated 138 patients, with 46 in each group.
The groups DS, D, and S were similar in terms of aver-
age age (53.26 ± 11.09, 53.33 ± 11.42, and 52.65 ± 11.56
years, respectively, p = 0.952). Their mean weight was
75.05 ± 15.55, 81.10 ± 14.39, and 71.08 ± 17.70 kg, and
the mean BMI was 28.37 ± 5.51, 30.78 ± 6.07 and
26.51 ± 5.21 kg/m2, respectively. The proportions of
obese subjects (BMI ≥ 30 kg/m2) in groups DS, D, and S
were 34.8%, 52.2%, and 17.4%, respectively. There were
significant differences between groups D and S in weight
(p = 0.012), BMI (p = 0.002), and the presence of obesity
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education, use of anxiolytics and alcohol consumption.
The proportion of patients who were taking antihyper-
tensives was different among groups DS (58.7%), D (71.7%),
and S (30.4%) (p< 0.001). The individuals within the DS
group used antihypertensives 3.2 times more than the S
group (OR: 3.2481; 95% CI: 1.38 to 7.67). Similarly, the pro-
portion of individuals who exercised at least two times per
week was different among groups DS (32.6%), D (58.7%),
and S (34.8%) (p=0.019), and the OR of group D compared
to group DS was 2.937 (95% CI: 1.25 to 6.88).
Most of the diabetic patients in the D and DS groups
were only taking oral antidiabetic drugs (50% and 61%,
respectively, p = 0.917).
There was no difference in the proportion of indivi-
duals with symptoms of depression or anxiety in the DS
group compared to groups D and S, and their scores on
subscales HAD-A and HAD-D were also similar
(Table 1). When only men were considered in the analy-
sis, those of D group were 85% less likely to exhibit
symptoms of anxiety (OR: 0.1481; 95% CI: 0.03 to 0.79)
and 8 times more likely to practice physical activity
twice or more per week than men of the DS group (OR:
8.028; 95% CI: 2.15 to 29.94). These results suggest that
the lower frequency of anxiety symptoms could have
been due to physical activity. Therefore, multiple logistic
regression was performed, and we observed that the fre-
quency of physical activity among men was not asso-
ciated with the prevalence of anxiety symptoms
(p = 0.328). There were no significant differences among
the three groups of men in the use of anxiolytics, the
consumption of alcohol, or the presence of obesity.
The proportion of participants who showed symptoms
of anxiety (50.7%) was higher than those who had symp-
toms of depression (34.1%) (p = 0.007), whereas 31.6%
had both symptoms. The mean value obtained on the
anxiety scale (8.05 ± 4.62) was also higher than the




HAD-A score (average± SD) 7.98 ± 4.07
HAD-A score≥ 8 (n/%) 23 (50.0%)
• Men 9 (19.6%)
• Women 14 (30.4%)
HAD-D score (average± SD) 6.17 ± 3.58
HAD-D score≥ 8 (n/%) 14 (30.4%)
• Men 5 (10.9%)
• Women 9 (19.5%)
*Analysis of variance; # chi-squared test.There was a moderate positive linear correlation
between depression and anxiety scores (Pearson
r = 0.5297; 95% CI: 0.40 to 0.64; p < 0.001). Based on
these results, a patient with symptoms of depression
(HAD-D subscale score ≥ 8) was 6.5 times more likely to
report symptoms of anxiety than those who did not
have symptoms of depression (OR: 6.5030; 95% CI:
2.87 to 14.75; p < 0.001) and vice versa.
The daily use of cigarettes, the average time of addic-
tion, the degrees of nicotine dependence measured
according to the FTND questionnaire, and the propor-
tion of smokers with high nicotine dependence were all
statistically similar between the S and DS groups
(Table 2).
Fagerström scores showed no significant correlation with
the scores obtained on the subscale of anxiety (p=0,735) or
depression (p=0,364). The nicotine-dependent patients
had an average anxiety score of 8.51±4.53, while non-
nicotine-dependent patients scored 8.32±4.25 (p=0.832).
The mean depression scores were also similar between the
two groups (6.46±4.01 and 5.65±3.80, respectively,
p =0.335). Thus, the prevalence of symptoms of anxiety
and depression were similar among nicotine dependents
(54,3% and 37.1%, respectively) and non-dependents (57,9%
and 28.1%, respectively).
Smokers, with and without diabetes, were similar to non-
smokers in terms of alcohol consumption (p=0.122) but
were different in terms of physical activity (p = 0.009).
The likelihood that an individual would practice physical
activity at least twice per week was almost 3 times higher
if the individual did not smoke (OR: 2.797; 95% CI: 1.35
to 5.8).
The proportion of men with high nicotine dependence
(43.5%) was similar to women (32.6%) (p= 0,284). How-
ever, the daily cigarette consumption was higher among
men than women (p= 0.018). Thus, the average Fager-
ström score obtained for the men (5.52 ± 1.96 points) was






7.37 ± 5.14 8.80 ± 4.58 0.330 *
18 (39.1%) 29 (63.0%) 0.072 #
2 (4.3%) 11 (23.9%) 0.011 #
16 (34.8%) 18 (39.1%) 0.440 #
6.74 ± 4.60 5.74 ± 4.18 0.516 *
18 (39.1%) 15 (32.6%) 0.657 #
6 (13%) 5 (10.9%) 0.922 #
12 (26.1%) 10 (21.7%) 0.664 #






Daily consumption (cigarettes/day) 20 (10–21.5) 15 (10–20) 0.370 *
• Men 20 (15–30) 20 (10–20) 0.925 *
• Women 10 (9–20) 15 (10–20) 0.820 *
Time of smoking (years) 36.74 ± 14.61 34.26 ± 14.80 0.573 #
Fagerström score 4.98 ± 2.50 5.04 ±1.58 0.881 #
Nicotine dependence
• High 18 (39.1%) 17 (37.0%) 0.999 +
• Medium or Low 28 (60.9%) 29 (63.0%)
Data are median (25th percentile–75th percentile), average ± SD, or absolute frequency (relative in %).
* Mann–Whitney U-test; # Student’s t test; + chi-squared test.
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tensive drugs, treatment of T2D, family history of
smoking, habit of smoking, nicotine dependence,
length of education, and physical activity were not
associated with the prevalence of anxiety or depression
symptoms (Table 3). There was no association between
daily or weekly consumption of alcohol and symptoms
of depression or nicotine dependence. However,
patients who consumed alcohol daily or weekly were
65% less likely to present symptoms of anxiety (OR: 0.35;
95% CI: 0.15 to 0.81). Because 69% of these patients were
men, multiple logistic regression was applied, which indi-
cated that alcohol consumption was not significantly
associated with the absence of symptoms of anxiety
(p = 0.111), but it was associated with male gender
(p < .001). There was no association between gender and
the habit of practicing physical activity (p = 0.612) or
duration of education (p = 0.999). Women showed
almost 5 times the likelihood of men to present the
symptoms of anxiety and 2.7 times the likelihood of
men to present symptoms of depression.
Marital status, gender, obesity, use of anxiolytic or
antihypertensive drugs, physical activity, family history
of smoking, and alcohol consumption showed no asso-
ciation with the degree of nicotine dependence (Table 4).
Participants who had ≥ 8 years of formal education were
2.57 times more likely to have high nicotine dependence
than those with less education.Discussion
In this study the prevalence of symptoms of depression
and anxiety in smokers with T2D was 30.4% and 50%,
respectively. There was no difference between the pro-
portion of individuals with symptoms of depression or
anxiety in the DS group and that of group D or S. Among
male patients with T2D, the smokers had a higher preva-
lence of anxiety symptoms than the non-smokers. Finally,
the degree of nicotine dependence showed no correlationwith the scores obtained on the subscale of anxiety or
depression.
Although the similar prevalence of depression among
people with diabetes who are smokers or non-smokers
was suggested by Lloyd et al. [15], other studies showed
a higher prevalence among smokers [12,14,31]. Unlike
the present study, none of the previously published stu-
dies evaluated only patients with T2D.
Epidemiological studies have found heterogeneity
among the prevalence of depression over 1 year and
throughout life in the general population. A systematic
review, using a pooled sample of studies, found a 1-year
prevalence of 4.1% and a lifetime prevalence of 6.7%
[32]. Other studies show that the prevalence of depres-
sive disorders in the general population ranges from 6.3
to 6.6% (annual) and 8.3 to 16.2% (lifetime) [33,34].
However, Haug et al. [35], using the same methods as
this study (HAD scale), found a prevalence of 10.4% for
symptoms of depression in a sample of 62,651 indivi-
duals from the Norwegian general population.
In Brazil, although it has been evaluated in different
places, in different sub-populations, and in different
ways, population-based studies have found a prevalence
of depression throughout life ranging from 2 to 16.8%
[36,37] and an annual rate of 7.1% [37]. Moreover, the
prevalence of depressive symptoms varies among differ-
ent subgroups of the general Brazilian population, for
example, 24.4% in individuals with epilepsy [38], 14 to
37% in hospitalized patients [39,40] and 8,5% among
college students [41].
Two meta-analyses evaluating depression in the popu-
lation with diabetes in relation to the general population
have been published. The prevalence of depression is
higher in diabetics compared to non-diabetics [22], and
the risk of depression is 24% higher in patients with T2D
[23]. The prevalence of depression in T2D patients var-
ies from 17.9 to 43.5% [24-26]. Thus, the high preva-
lence of symptoms of depression in groups DS, D, and S
of this study may be explained by its association with
Table 3 Analysis of factors associated with anxiety and depression among the study participants
Variables n HAD-A≥ 8 score p-value OR # (95% CI) HAD-D≥ 8 score p-value OR # (CI 95%)
n (%) n (%)
Marital status
Non-married 42 24 (57.1) 0.320 1.0 13 (31.0) 0.611 1.0
Married 96 46 (47.9) 0.69 (0.33 to 1.43) 34 (35.4) 1.22 (0.56 to 2.66)
Obesity (BMI≥ 30)
No 90 43 (47.8) 0.344 1.0 32 (35.6) 0.611 1.0
Yes 48 27 (56.3) 1.41 (0.69 to 2.84) 15 (31.3) 0.82 (0.39 to 1.74)
Use of anxiolytics
No 123 61 (49.6) 0.290 1.0 40 (32.5) 0.192 1.0
Yes 15 9 (60.0) 1.86 (0.59 to 5.86) 7 (46.7) 2.10 (0.69 to 6.39)
Use of antihypertensives 64 33 (51.6) 0.855 1.0 18 (28.1) 0.173 1.0
No 74 37 (50.0) 0.94 (0.48 to 1.83) 29 (39.2) 1.65 (0.8 to 3.37)
Yes
Treatment of T2D*
With insulin 63 28 (44.4) 0.973 1.0 23 (36.5) 0.609 1.0
Without insulin 29 13 (44.8) 1.02 (0.42 to 2.46) 9 (31.0) 0.78 (0.31 to 2.0)
Smoking family history
Non-smoking parents 33 12 (36.4) 0.062 1.0 11 (33.3) 0.920 1.0
Mother, Father, or both smoked 105 58 (55.2) 2.16 (0.96 to 4.84) 36 (34.3) 1.04 (0.46 to 2.39)
Smoking habit
Non-smokers 46 18 (39.1) 0.056 1.0 18 (39.1) 0.375 1.0
Smokers 92 52 (56.5) 2.02 (0.98 to 4.16) 29 (31.5) 0.72 (0.34 to 1.50)
Nicotine dependence**
Low or medium 57 33 (57.9) 0.735 1.0 16 (28.1) 0.364 1.0
High (FTND score≥ 6) 35 19 (54.3) 0.86 (0.37 to 2.02) 13 (37.1) 1.51 (0.62 to 3.71)
Alcohol consumption:
No or≤monthly 106 60 (56.6) 0.014 1.0 39 (36.8) 0.221 1.0
Daily or weekly 32 10 (31.2) 0.35 (0.15 to 0.81) 8 (25.0) 0.57 (0.23 to 1.40)
Length of schooling:
< 8 years 82 45 (54.9) 0.239 1.0 24 (29.3) 0.152 1.0
≥ 8 years 56 25 (44.6) 0.66 (0.33 to 1.31) 23 (41.1) 1.68 (0.82 to 3.44)
Gender:
Male 69 22 (31.9) < 0.001 1.0 16 (23.2) 0.008 1.0
Female 69 48 (69.6) 4.88 (2.38 to 10.04) 31 (44.9) 2.70 (1.30 to 5.63)
Physical Activity
No or≤ 1x/week 80 45 (56.2) 0.129 1.0 25 (31.2) 0.414 1.0
From 2 to 5x/week 58 25 (43.1) 0.59 (0.30 to 1.17) 22 (37.9) 1.34 (0.66 to 2.74)
* Diabetic patients. ** Smoking patients # Logistic regression.
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smoking, which is a harmful behavior to health and is
also associated with depression [12,14,21].
Regarding the frequency of anxiety symptoms in the
general population, Bourdon et al. [33] estimated the
prevalence of anxiety disorders in the general population
of the U.S. at 10.1% (annual) and 14.6% (lifetime). Twointernational studies that used the HAD scale found a
prevalence of 15.3% in a sample of 62,651 individuals in
Norway [35] and 15% in 2061 normoglycemic indivi-
duals in the Netherlands [26]. In Brazil, the prevalence
of any anxiety disorder ranges from 9.6 to 12.5% (life-
time) [36,37], 7.7% (annual) [37], 6% (monthly) [37], and
36.2% (one time) [42]. Although it is difficult to compare
Table 4 Analysis of factors associated with nicotine dependence among smokers
Variable n Fagerström score≥ 6 p-value* OR* (95% CI)
n (%)
Gender:
Male 46 20 (43.5) 0.284 1.0
Female 46 15 (32.6) 0.63 (0.27 to 1.47)
Marital status
Non-married 29 15 (51.7) 0.070 1.0
Married 63 20 (31.7) 0.43 (0.18 to 1.07)
Obesity (BMI≥ 30)
No 68 26 (38.2) 0.949 1.0
Yes 24 9 (37.5) 0.97 (0.37 to 2.53)
Use of anxiolytics
No 78 30 (38.5) 0.973 1.0
Yes 14 5 (35.7) 1.02 (0.31 to 3.41)
Use of antihypertensives
No 51 21 (41.2) 0.491 1.0
Yes 41 14 (34.1) 0.74 (0.32 to 1.74)
Physical activity
No or≤ 1x/week 61 26 (42.6) 0.207 1.0
From 2 to 5x/week 31 9 (29.0) 0.55 (0.22 to 1.39)
Smoking family history:
Non-smoking parents 16 7 (43.7) 0.606 1.0
Mother, Father, or both smoked 76 28 (36.8) 0.75 (0.25 to 2.24)
Alcohol consumption:
No or≤monthly 67 22 (32.8) 0.096 1.0
Daily or weekly 25 13 (52.0) 2.22 (0.87 to 5.65)
Length of schooling:
< 8 years 55 16 (29.1) 0.033 1.0
≥ 8 years 37 19 (51.4) 2.57 (1.08 to 6.13)
*Logistic regression.
Osme et al. Diabetology & Metabolic Syndrome 2012, 4:39 Page 7 of 10
http://www.dmsjournal.com/content/4/1/39because the data collection methods differ, but it is clear
that the prevalence of anxiety varies widely. Among spe-
cific groups, different prevalence values have been found:
16.5% among college students [41], 39.4% among epilep-
tics [38], and 46% in hospitalized patients [40].
Anxiety is associated with smoking [12] and nicotine
dependence [11,13]. Despite the limited literature on the
prevalence of anxiety in smokers with diabetes, some stu-
dies show a higher prevalence of anxiety symptoms
among subjects with diabetes smokers than non-smokers
[14,15]. In the diabetic population, several studies show
that the prevalence of anxiety varies from 19.9 to 57.9%
[12,15,25,26]. A systematic review found that generalized
anxiety disorders are present in 14% and anxiety symp-
toms in approximately 40% of people with diabetes. The
prevalence was similar among individuals with T1D and
T2D (41.3% vs. 42.2%, p = 0.80) [43]. Thus, the similarprevalence of anxiety symptoms found in the three
groups of this study, which were higher than the rates
found in the general population, can be explained by its
association with diabetes [12,21,25] and smoking [12,21].
In a study examining the psychometric properties of
the HAD scale at the population level, the authors found
a HAD-A subscale score of 4.06 and HAD-D subscale
score of 3.87 [44]. According to the present study, the
average scores of 8.05 for anxiety and 6.22 for depres-
sion suggest a higher prevalence of symptoms of anxiety
and depression in the sample studied when compared to
the general population. Our averages are closer to the
values found in hospitalized patients reported in the
study of Delfini et al. [40], which found mean scores of
7.9 on HAD-A and 6.92 on HAD-D.
The results of this study reinforce the results reported
by other authors that show a positive linear correlation
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higher prevalence of depression and/or anxiety disorders
in women than in men [11,21,25,40,43].
A survey conducted by the German Ministry of Science
found a 9.4% annual prevalence of nicotine dependence
in a sample of approximately 3,300 individuals in the
non-institutionalized population of Germany. Among
1491 regular smokers in the study, the prevalence was
26.2% [46]. In the U.S., based on a sample of 4,414 smo-
kers, Breslau et al. [28] estimated the prevalence of nico-
tine dependence to be 24%. In Brazil, a study conducted
in Rio Grande do Sul in the general population of smo-
kers without tobacco-related diseases founds 13.3% of
high nicotine dependence [11]. In another study invol-
ving hospitalized patients, 21% were regular smokers,
and among these, 26% had high nicotine dependence
[47].
The presence of nicotine dependence varies accord-
ing to age [28,37]. Breslau et al. [13] did not identify
any smokers with high nicotine dependence, which is
likely due to the youth of their sample (average age 26
years). The study of Castro et al. [11] observed high
nicotine dependence in 13.3% of smokers, whose aver-
age age was 37.7 years. In another study involving 573
elderly (≥ 60 years) admitted to long-term institutions
in Brazil, 25.9% of the smokers had high nicotine depen-
dence [48]. Therefore, the high percentages of nicotine
dependence among smokers with diabetes (39.1%) and
non-diabetics (38.5%) of the present study (mean age 53
years) may have been due in part to age.
Fagerström and Furberg [49] compared 15 studies
conducted in 13 different countries that used FTND,
and they found that scores ranged from 2.8 to 4.6
(average 3.6). Germany and Norway had the lowest
scores, the U.S. and Sweden had the highest. The
results from the latter two countries resemble those of
the present study because the average FTND scores in
both groups of smokers, with and without diabetes,
were approximately 5 points.
The high rates of anxiety and depression among nicotine
dependents in the present study (54.3% and 37.1%, respec-
tively) are in accordance with the prevalences reported in
the literature: 22 to 62.3% for any anxiety disorder and 16.6
to 39% for major depression [13,50]. However, the lack of
association between nicotine dependence and symptoms of
anxiety and depression differs from other studies [11,13].
There is no clear explanation for this difference, but the
studies involved different types of subjects and therefore
would not necessarily achieve the same results. While two
studies [11,13] evaluated the general population of smokers,
in this study the sample was composed of outpatients.
Moreover, the non-nicotine-dependent individuals of the
DS group were all diabetic, so the presence of T2D could
have influenced the prevalence of symptoms.Interestingly, this study found a negative association of
smoking, disregarding the presence or absence of dia-
betes or nicotine dependence, with physical activity.
Among men, smoking was also associated with a higher
prevalence of anxiety symptoms. The interactions among
all of these variables are clearly complex, but symptoms
of depression and anxiety have been strongly associated
with some adverse health behaviors, such as smoking,
alcohol consumption, and physical inactivity [12,21,25].
Therefore, these behaviors are likely interrelated. For
example, smoking is associated with low physical activity,
a diet low in fruits and vegetables, and high alcohol con-
sumption [3]. Given that physical activity promotes bet-
ter blood glucose control, lipid profile, and blood
pressure in patients with T2D [51] and that smoking is a
risk factor for macro- and microvascular complications
in individuals with diabetes [9,10,18], the results of the
present study reinforce the importance of smoking cessa-
tion for smokers T2D.
Unlike the present study, Breslau et al. [13] observed
that the amount of education was inversely related to
the degree of nicotine dependence. It has not been pos-
sible to find a convincing explanation for this difference.
Khuwaja et al. [25] identified hypertension as an inde-
pendent factor associated with symptoms of anxiety and
depression, but the present study showed no such asso-
ciation. This may have been due to the small number of
individuals evaluated in this regard. The higher propor-
tion of smokers with diabetes who used antihyperten-
sives when compared to smokers without diabetes was
likely due to the diabetes affects the heart and blood ves-
sels. Cardiovascular disease is the most common cause
of death and disability among subjects with diabetes [4].
If there are differences in the prevalence of symptoms
of depression and anxiety between smokers with and
without T2D, it is likely that those differences are very
little. Thus, we wish to emphasize that this study has
limitations because of the small number of patients stu-
died and the possible type II errors. However, the only
existing study aiming to assess depression and anxiety in
diabetic smokers recruited only 83 patients with type 1
diabetes and only 19 of these were smokers [14].Conclusions
The prevalence of depression and anxiety among smo-
kers with and without T2D and non-smokers T2D is
similar. Among male individuals with T2D, the smokers
have more symptoms of anxiety than the non-smokers.
There is no difference in the prevalence of nicotine
dependence between smokers with and without diabetes.
The presence of symptoms of anxiety or depression is
similar between patients who are dependent and not
dependent on nicotine.
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